Llama immunization with full-length VAR2CSA generates cross-reactive and inhibitory

single-domain antibodies against the DBL1X domain

Sofia Nunes-Silva^{a,b,c,d}, Stéphane Gangnard^{a,b,c,d}, Marta Vidal^{a,b,c,d}, Anneleen Vuchelen^{e,f},

Sebastien Dechavanne^{a,b,c,d}, Sherwin Chan^g, Els Pardon^{e,f}, Jan Steyaert^{e,f}, Stephanie

Ramboarina^{e,f}, Arnaud Chêne^{a,b,c,d} and Benoît Gamain^{a,b,c,d,*}.

Inserm UMR 1134, Paris, France^a; Université Paris Diderot, Sorbonne Paris Cité,

UMR_S1134 Paris, France^b; Institut National de la Transfusion Sanguine, Paris, France^c;

Laboratory of excellence GR-Ex, Paris, France^d; VIB, Structural Biology Research Center,

Brussels, Belgiume, Structural Biology Brussels, Vrije Universiteit Brussel, Belgiumt,

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm,

Sweden^g.

*Corresponding author:

Benoît Gamain

UMR S1134


Institut National de la Transfusion Sanguine

6 rue Alexandre Cabanel, 75015 Paris, France


Tel: +33 (0) 1 44 49 30 01

Fax: +33 (0) 1 43 06 50 19

E-mail: benoit.gamain@inserm.fr



Supplementary Figure S1. Nanobody expression and purification. The coomassie blue stained gel contains the starting material (SM) of the IMAC purification (corresponding to the periplasmic extract from harvested bacteria), flow-through (FT), wash (W) and eluted fractions (E1 and E2) for the VHH905.



Supplementary Figure S2. Sensorgram showing interaction of VHH867 with VAR2CSA. Full-length recombinant VAR2CSA (3D7-DBL1X-6 ϵ) was immobilized on the chip and nanobodies were injected at 10 different concentrations from 1 μ M to 1.95 nM, as indicated above some of the corresponding curves.